A recent commentary published by a Minnesota news outlet is drawing attention to how the state's law on per- and polyfluoroalkyl substances — often called "forever chemicals" or PFAS — may affect the medical device industry. The piece, written by a former U.S. deputy surgeon general, argues that while the law's environmental goals are sound, its reporting requirements could have unintended effects on patient access to certain devices. For businesses, healthcare providers, and consumers, the situation raises a set of legal and regulatory questions worth unpacking.
What Happened
Minnesota has enacted a broad PFAS statute, sometimes referred to by the shorthand "Amara's Law." According to the commentary, the law includes a 2032 prohibition on the sale of many products containing intentionally added PFAS, but carves out FDA-regulated medical devices and drugs from that sales ban.
However, the reporting requirements — scheduled to begin taking effect in 2026 — reportedly do not include the same carve-out for medical devices. Under those requirements, manufacturers selling products that contain intentionally added PFAS in Minnesota generally must file detailed, product-by-product disclosures with the state's Pollution Control Agency and update them each year. The commentary states that civil penalties for failing to report may reach up to $30,000 per day, and that products whose makers do not file generally cannot be sold in the state.
The author raises concerns that this could pressure manufacturers of devices such as stents, sutures, catheters, contact lenses, pacemakers, and sterile packaging to either invest heavily in compliance or pull certain products from the Minnesota market. The piece cites reporting that the FDA has reviewed the safety of the specific fluoropolymer PFAS used in many medical devices and reportedly found no evidence of patient harm.
It's important to note this is an opinion commentary, not a court ruling or agency enforcement action. The commentary is a policy critique — but it highlights legal mechanics that companies and their counsel are almost certainly reviewing.
Why It Matters Legally
At first glance this looks like an environmental story. But for the business and corporate law community, it sits at the intersection of several areas:
- Regulatory compliance: Any state-level reporting regime with per-day civil penalties creates significant compliance risk. Companies typically need internal systems to identify covered products, gather chemical data from suppliers, and file on time.
- Contract and supply chain law: Manufacturers often depend on component suppliers to disclose what's in their inputs. When a new disclosure duty appears, contracts may need to be revisited to allocate responsibility for accurate information.
- Preemption questions: Federally regulated products — especially FDA-cleared medical devices — sometimes raise questions about whether state disclosure rules conflict with federal oversight. Courts generally analyze these disputes case by case.
- Product liability exposure: Public disclosures about chemical content can, in some circumstances, be used later in civil litigation. Companies generally weigh how filings may be interpreted years down the line.
- Market access decisions: A business decision to withdraw a product from one state is itself a corporate governance issue, with implications for shareholders, hospital customers, and long-term contracts.
Who Could Be Affected
Even though the underlying commentary focuses on patients, the legal ripple effects reach many groups:
- Device manufacturers and med-tech companies, particularly those with significant Minnesota operations or sales.
- Component and material suppliers, who may be asked to certify or disclose PFAS content to downstream customers.
- Hospitals, clinics, and group purchasing organizations, which may face changes in product availability or pricing.
- Distributors and retailers of consumer products that contain PFAS but do not fall under the device carve-out.
- Investors and corporate directors, who generally track regulatory risk as part of their oversight duties.
- Patients and consumers, who may see changed product availability and, in some cases, could bring claims if they believe they were harmed or misled — though any such claim would depend heavily on specific facts.
How Cases Like This Generally Work
When a new state-level chemical disclosure law takes effect, the legal work generally unfolds in stages.
First, in-house and outside counsel typically conduct a product inventory: identifying which items sold in the state contain the regulated substance, whether intentionally added or as an unavoidable trace. This often involves questionnaires to suppliers and review of technical data sheets.
Second, lawyers usually analyze the scope of any exemptions. Here, the reported carve-out for FDA-regulated devices from the 2032 sales ban does not, according to the commentary, extend to the reporting duty. Distinctions like that generally drive compliance strategy.
Third, companies may consider challenges or advocacy. Businesses can generally comment during rulemaking, request guidance from the agency, or in some cases bring litigation arguing that a state law is preempted by federal law, unconstitutionally vague, or otherwise unlawful. The outcome of any such challenge would depend on the specific statute, the record, and controlling case law.
Fourth, if enforcement is initiated, cases typically move through administrative processes first — notices of violation, opportunities to cure, and negotiated penalties — before reaching court. Per-day penalty structures generally create pressure to resolve issues quickly rather than litigate.
Fifth, on the private-litigation side, disclosures filed under state law can sometimes surface in later disputes. Plaintiffs' lawyers may point to filings as evidence of what a company knew; defense lawyers may point to those same filings as evidence of transparency and good-faith compliance. How that plays out generally depends on the underlying facts.
Timelines vary. Rulemaking cycles often run months to years. Enforcement actions can resolve in weeks or stretch across multiple years if litigated.
What to Watch Next
Several developments would be worth watching in follow-up reporting and public records:
- Agency guidance from Minnesota's Pollution Control Agency clarifying how the reporting requirement applies to medical devices and what level of product-by-product detail is expected.
- Legislative activity — including any proposed amendments that would expand exemptions for FDA-regulated products or adjust deadlines.
- Industry filings as the first reporting deadline approaches, which the commentary places in September 2026.
- Litigation, if any manufacturer or trade group challenges the reporting rule on preemption or other grounds.
- Enforcement announcements from state authorities against companies that miss the deadline.
- Corporate disclosures in securities filings from public device makers describing how they are responding to Minnesota's requirements.